NCT02400801

Brief Summary

Does prolonged GnRH downregulation prior to ART improve the clinical pregnancy rate in postoperative endometriosis patients? (A single centre randomised controlled trial)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
166

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2013

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

March 11, 2015

Completed
16 days until next milestone

First Posted

Study publicly available on registry

March 27, 2015

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 26, 2018

Completed
Last Updated

July 10, 2024

Status Verified

July 1, 2024

Enrollment Period

4.5 years

First QC Date

March 11, 2015

Last Update Submit

July 9, 2024

Conditions

Keywords

endometriosisinfertilityassisted reproductive technology

Outcome Measures

Primary Outcomes (1)

  • clinical pregnancy rate per initiated ART cycle

    participants will be followed for the duration of the ART cycle including the pregnancy test, an expected average of 10 weeks in the active comparator group and an expected average of 18 weeks in the experimental group

Study Arms (2)

oral oestroprogestogen pre-treatment

ACTIVE COMPARATOR

preparation with oral oestroprogestogens prior to downregulation in an assisted reproductive technology treatment (ART) cycle

Drug: ethinylestradiol + dienogest

gonadotropin-releasing hormone (GnRH) pre-treatment

EXPERIMENTAL

preparation with gonadotropin-releasing hormone (GnRH) analogues prior to downregulation in an assisted reproductive technology treatment (ART) cycle

Drug: triptorelin

Interventions

gonadotropin-releasing hormone (GnRH) agonist

Also known as: decapeptyl
gonadotropin-releasing hormone (GnRH) pre-treatment

oral oestroprogestogen

Also known as: Louise
oral oestroprogestogen pre-treatment

Eligibility Criteria

Age18 Years - 39 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • histologically proven endometriosis with complete treatment of all endometriosis lesions during laparoscopy
  • only first three ART cycles
  • normal uterine cavity
  • Eligible for ovarian stimulation with long agonist protocol

You may not qualify if:

  • FSH\>20 IU/L
  • presence of large intramural fibroids (\> 3 cm)
  • \<4 oocytes obtained in any previous fresh ART cycle
  • ART with sperm derived from testicular biopsy
  • ART with Preimplantation Genetic Diagnosis/Screening

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UZ Leuven

Leuven, 3000, Belgium

Location

Related Publications (1)

  • Tomassetti C, Beukeleirs T, Conforti A, Debrock S, Peeraer K, Meuleman C, D'Hooghe T. The ultra-long study: a randomized controlled trial evaluating long-term GnRH downregulation prior to ART in women with endometriosis. Hum Reprod. 2021 Sep 18;36(10):2676-2686. doi: 10.1093/humrep/deab163.

MeSH Terms

Conditions

EndometriosisInfertility

Interventions

Triptorelin PamoateEthinyl Estradioldienogest

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

Gonadotropin-Releasing HormonePituitary Hormone-Releasing HormonesHypothalamic HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsOligopeptidesNerve Tissue ProteinsProteinsNorpregnatrienesNorpregnanesNorsteroidsSteroidsFused-Ring CompoundsPolycyclic CompoundsEstrogenic Steroids, AlkylatedEstradiol CongenersGonadal Steroid HormonesGonadal Hormones

Study Officials

  • Thomas M D'Hooghe, MD, PhD

    UZ Leuven

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 11, 2015

First Posted

March 27, 2015

Study Start

June 1, 2013

Primary Completion

December 1, 2017

Study Completion

January 26, 2018

Last Updated

July 10, 2024

Record last verified: 2024-07

Locations